115.30
전일 마감가:
$113.74
열려 있는:
$112.4
하루 거래량:
1.96M
Relative Volume:
1.19
시가총액:
$243.56B
수익:
$55.19B
순이익/손실:
$13.65B
주가수익비율:
16.81
EPS:
6.86
순현금흐름:
$16.81B
1주 성능:
-2.04%
1개월 성능:
-6.34%
6개월 성능:
+10.10%
1년 성능:
+2.85%
노바티스 ADR Stock (NVS) Company Profile
NVS을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
NVS
Novartis Ag Adr
|
115.30 | 220.18B | 55.19B | 13.65B | 16.81B | 6.86 |
![]()
LLY
Lilly Eli Co
|
762.33 | 664.39B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
167.33 | 396.75B | 90.63B | 22.66B | 16.40B | 9.35 |
![]()
ABBV
Abbvie Inc
|
195.22 | 333.89B | 58.33B | 3.76B | 15.39B | 2.10 |
![]()
MRK
Merck Co Inc
|
79.29 | 196.16B | 63.62B | 16.41B | 17.04B | 6.49 |
노바티스 ADR Stock (NVS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-13 | 다운그레이드 | UBS | Buy → Neutral |
2025-02-12 | 개시 | Morgan Stanley | Underweight |
2025-02-04 | 업그레이드 | Deutsche Bank | Hold → Buy |
2024-12-04 | 다운그레이드 | HSBC Securities | Hold → Reduce |
2024-09-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
2024-09-05 | 다운그레이드 | Goldman | Buy → Neutral |
2024-09-03 | 다운그레이드 | Jefferies | Buy → Hold |
2024-07-19 | 다운그레이드 | Deutsche Bank | Buy → Hold |
2024-05-30 | 개시 | Goldman | Buy |
2024-02-23 | 개시 | BMO Capital Markets | Market Perform |
2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
2024-01-16 | 재개 | UBS | Buy |
2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
2023-09-25 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
2023-07-14 | 개시 | HSBC Securities | Buy |
2023-04-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
2023-03-27 | 업그레이드 | Deutsche Bank | Sell → Hold |
2023-01-26 | 다운그레이드 | Citigroup | Buy → Neutral |
2022-12-05 | 업그레이드 | Stifel | Hold → Buy |
2022-09-15 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
2022-05-09 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
2022-01-10 | 재개 | Citigroup | Buy |
2021-12-14 | 다운그레이드 | Redburn | Buy → Neutral |
2021-12-06 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
2021-12-03 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
2021-09-20 | 다운그레이드 | Deutsche Bank | Hold → Sell |
2021-03-22 | 개시 | Bernstein | Mkt Perform |
2021-03-10 | 다운그레이드 | Argus | Buy → Hold |
2021-02-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
2021-01-15 | 개시 | Deutsche Bank | Buy |
2020-09-29 | 개시 | Berenberg | Buy |
2020-09-10 | 업그레이드 | UBS | Neutral → Buy |
2020-09-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2020-06-15 | 업그레이드 | Citigroup | Neutral → Buy |
2020-03-10 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
2020-02-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
2019-04-25 | 업그레이드 | Guggenheim | Neutral → Buy |
2019-04-25 | 업그레이드 | Liberum | Hold → Buy |
2019-04-10 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
2019-01-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2018-12-11 | 재개 | Jefferies | Buy |
2018-10-09 | 개시 | Guggenheim | Neutral |
2018-09-10 | 업그레이드 | BofA/Merrill | Underperform → Buy |
2018-05-29 | 다운그레이드 | HSBC Securities | Buy → Hold |
2018-05-25 | 업그레이드 | Credit Suisse | Underperform → Neutral |
2018-01-25 | 재확인 | Leerink Partners | Outperform |
2017-12-06 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
2017-07-26 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
2017-07-05 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
2017-03-09 | 개시 | Liberum | Buy |
모두보기
노바티스 ADR 주식(NVS)의 최신 뉴스
Pharma Stocks Slump on Presidential Ultimatum To Cut Prices - Morningstar
Sustainable dividends from European stocks poised to benefit from the tariff wars - The Globe and Mail
Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate - Benzinga
NVS’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Novartis Holds a Strong Branded Drug Portfolio, Supporting Steady Long-Term Growth - Morningstar
Novartis Beats On Q2 Earnings And Sales, CFO Retires, Stock Down - Barchart.com
Novartis ADR earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria
Novartis Earnings: Double-Digit Sales Growth Supports Another Upgrade to Full-Year Guidance - Morningstar
Will Key Drugs Maintain Momentum For Novartis In Q2 Earnings? - Barchart.com
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS) - Barchart.com
Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study - TradingView
Incyte Gains 9.2% In Three Months: Buy, Hold Or Sell The Stock? - Barchart.com
5 Large Drug Stocks That Are Poised To Ride On Sector Recovery - Barchart.com
NVO Stock Gains After Parvus Asset Management Builds Stake - Barchart.com
The Novartis Oncology Young Canadian Investigator Awards (NOYCIA) returns for its 22nd year at ASCO 2025 - Barchart.com
Bristol Myers Collaborates With BNTX For Oncology Candidate - Barchart.com
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Why Value Investing Has Worked Better Outside the US - Morningstar
Which Industries are shaken when Trump's tariff stick swings towards the EU? - 富途牛牛
Regeneron Initial Data On Multiple Myeloma Drug Encouraging - Barchart.com
Bybit Gold & FX now supports stock trading: Explore new markets! - Bybit Announcement
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug - Yahoo Finance
Novartis Canada extends Health Equity Initiative effort, fueling innovation and impact for second year - Barchart.com
NVS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Novartis Earnings: Strong First-Quarter Supports Increased Full-Year Guidance - Morningstar
Novartis ADR earnings beat by $0.20, revenue topped estimates - Investing.com
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar
Novartis Beats On Q1 Earnings And Sales, Raises Guidance, Stock Up - Barchart.com
Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up - Zacks Investment Research
Roche to invest US$50-billion in U.S. to avoid Trump tariffs, create 12,000 jobs - The Globe and Mail
Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? - Yahoo Finance
노바티스 ADR (NVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):